Tumor surveillance by circulating microRNAs: a hypothesis

Ivan Igaz · Peter Igaz

Received: 16 April 2014 / Revised: 7 July 2014 / Accepted: 10 July 2014 / Published online: 19 July 2014
© The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract A growing body of experimental evidence supports the diagnostic relevance of circulating microRNAs in various diseases including cancer. The biological relevance of circulating microRNAs is, however, largely unknown, particularly in healthy individuals. Here, we propose a hypothesis based on the relative abundance of microRNAs with predominant tumor suppressor activity in the blood of healthy individuals. According to our hypothesis, certain sets of circulating microRNAs might function as a tumor surveillance mechanism exerting continuous inhibition on tumor formation. The microRNA-mediated tumor surveillance might complement cancer immune surveillance.

Keywords Nascent tumor · Elimination · Reprogramming · Microvesicle

Introduction

MicroRNAs, the endogenous mediators of RNA interference, have been established as major epigenetic factors in posttranscriptional gene expression regulation. MicroRNAs are encoded by separate genes that are often clustered and undergo a complex maturation process giving rise to 22–25 nucleotide long single-stranded mature microRNA molecules targeting the 3' non-coding region of messenger RNAs (mRNA) [1]. MicroRNAs either induce target mRNA degradation or inhibition of translation. Approximately, 30–60% of human protein-coding genes are subjected to microRNA-based regulation [2]. MicroRNAs have pleiotropic actions and are implicated in the regulation of several basic cell biological processes (cell cycle, cell proliferation, apoptosis, etc.), ontogenesis, immune response, hormone secretion, etc. [1]. Alterations in tissue microRNA expression profiles have been associated with several diseases including cancer [2]. MicroRNAs can be classified following the classical oncogene–tumor suppressor dichotomy: overexpressed microRNAs in tumors can be regarded as oncogenes, whereas underexpressed microRNAs are tumor suppressors [3]. The oncogene–tumor suppressor activity of a given microRNA, however, is not absolute, but depends on the cellular context. The same microRNA can be oncogenic in one tissue, but might behave as a tumor suppressor in another. Some microRNAs, however, have either predominant oncogenic or tumor suppressor activity observed in many different tissues (e.g., hsa-miR-21, hsa-miR-17/92 families are oncogenic, hsa-miR-15/16, hsa-let-7 families are tumor suppressors) [4–7].

Numerous reports underline the relevance of tissue microRNAs both in normal and pathological conditions. Recent data appear to add a further layer of complexity to the biological relevance of microRNAs, as secreted microRNAs have been found in body fluids (blood serum or plasma, urine, semen, saliva, etc.) [8, 9]. MicroRNAs are supposed to enter body fluids via three major mechanisms: (1) passive release from damaged tissue, (2) active secretion in cell-borne membrane vesicles (exosomes, microvesicles and apoptotic bodies), (3) active secretion in macromolecular complexes associated with Argonaute (Ago) proteins (among other still unidentified proteins) and
Table 1 The 20 most abundant microRNAs in blood samples of healthy individuals from 5 studies involving 61 samples

| MicroRNA   | Fold | MicroRNA   | Fold | MicroRNA   | Fold | MicroRNA   | Fold | MicroRNA   | Fold | MicroRNA   | Fold |
|------------|------|------------|------|------------|------|------------|------|------------|------|------------|------|
| hsa-miR-544 | 5.1982 | hsa-miR-451a | 59.1044 | hsa-miR-923 | 199.4318 | hsa-miR-302a | 2.5641 | hsa-miR-451 | 1.4702 |
| hsa-miR-451 | 2.2491 | hsa-miR-486-5p | 28.8059 | hsa-miR-451 | 36.3352 | hsa-miR-145 | 2.3146 | hsa-miR-16 | 1.2892 |
| hsa-miR-302d | 2.1451 | hsa-miR-223-3p | 11.1201 | hsa-miR-1202 | 12.5284 | hsa-miR-551a | 1.5667 | hsa-miR-486-5p | 1.2353 |
| hsa-miR-504 | 2.0654 | hsa-miR-15b-5p | 8.8803 | hsa-miR-1225-5p | 5.1591 | hsa-miR-582-5p | 1.5053 | hsa-miR-19b | 1.1863 |
| hsa-miR-486-5p | 2.0222 | hsa-miR-92a-3p | 4.8054 | hsa-miR-671-5p | 4.0057 | hsa-miR-181c | 1.3988 | hsa-miR-92a | 1.1433 |
| hsa-miR-21 | 2.0120 | hsa-miR-16-5p | 7.0969 | hsa-miR-1299 | 3.4517 | hsa-miR-548c-5p | 1.2898 | hsa-miR-223 | 1.1348 |
| hsa-miR-550 | 1.9378 | hsa-miR-25-3p | 5.7728 | hsa-miR-652 | 1.7898 | hsa-miR-338-3p | 1.2334 | hsa-miR-638 | 1.1233 |
| hsa-let-7a | 1.6534 | hsa-let-7a-5p | 3.1115 | hsa-miR-324-3p | 1.6818 | hsa-miR-142-5p | 1.2326 | hsa-miR-22 | 1.1192 |
| hsa-miR-221 | 1.6534 | hsa-miR-140-3p | 2.3809 | hsa-miR-144 | 1.6222 | hsa-miR-1225-5p | 1.1149 | |
| hsa-miR-622 | 1.4578 | hsa-miR-107 | 2.0332 | hsa-miR-1268 | 1.4205 | hsa-miR-26b | 1.1733 | hsa-miR-720 | 1.0955 |
| hsa-miR-223 | 1.4578 | hsa-miR-185-5p | 2.0187 | hsa-miR-320d | 1.2528 | hsa-miR-29a | 1.1693 | hsa-miR-21 | 0.8189 |
| hsa-miR-380 | 1.3665 | hsa-miR-30c-5p | 1.9062 | hsa-miR-16 | 1.2386 | hsa-miR-1537 | 1.1631 | hsa-miR-1207-5p | 1.0656 |
| hsa-miR-202 | 1.2831 | hsa-miR-425-5p | 1.7028 | hsa-miR-142-3p | 1.2187 | hsa-miR-199a-5p | 1.1227 | hsa-miR-195 | 1.0552 |
| hsa-miR-20a | 1.1868 | hsa-miR-22-3p | 1.5608 | hsa-miR-1287 | 1.2159 | hsa-miR-769-5p | 1.1190 | hsa-miR-320c | 0.9464 |
| hsa-miR-122 | 1.1716 | hsa-let-7f-5p | 1.4027 | hsa-miR-1246 | 1.1903 | hsa-let-7i | 1.1275 | hsa-miR-1202 | 0.4567 |
| hsa-let-7g | 1.1232 | hsa-miR-103a-3p | 1.3318 | hsa-miR-223 | 1.1449 | hsa-miR-223 | 1.1106 | hsa-miR-20a | 0.2200 |
| hsa-miR-150 | 1.1087 | hsa-miR-7b-5p | 1.3038 | hsa-miR-188-5p | 1.1420 | hsa-miR-409-3p | 1.1087 | hsa-miR-25 | 1.0161 |
| hsa-miR-551a | 1.0221 | hsa-miR-19b-3p | 1.3038 | hsa-miR-1246 | 1.1903 | hsa-miR-142-3p | 1.1275 | hsa-miR-15a | 0.1519 |
| hsa-miR-25 | 1.0052 | hsa-miR-15a-5p | 1.0429 | hsa-miR-760 | 1.0710 | hsa-miR-130b | 1.0092 | hsa-miR-106b | 0.138 |
| hsa-miR-623 | 1.0000 | hsa-miR-320d | 1.0000 | hsa-miR-720 | 1.0000 | hsa-miR-20a | 1.0000 | hsa-miR-19a | 1.0000 |

Expression results were downloaded from the Gene Expression Omnibus (GSE25609, GSE53179, GSE39833, GSE41922 and GSE50867). MicroRNAs are ranked by their expression values. The table shows the top 20 microRNA from each study. Data processing and analysis were performed by own programs developed in JAVA program language. MicroRNAs in bold have been found to be relatively abundant in three independent studies. (MicroRNAs denoted with -3p and -5p are transcribed from the same microRNA gene, and represent the two arms of the microRNA precursor)

Values are calculated in relation the 20th highly expressed microRNA (−fold)

high-density lipoprotein (HDL) particles [10]. The cellular origin of blood-borne serum/plasma microRNAs is not fully explored, but a major source could be represented by blood cells including red and white blood cells, and platelets [11] and the liver [12].

The extracellular microRNAs are surprisingly stable and their analysis is possible even from archived body fluid samples. Circulating blood-borne microRNAs are being investigated as potent minimally invasive biomarkers of several diseases including tumors [13, 14].

Despite their clear relevance as disease markers, the biological relevance of blood-borne microRNAs is largely unknown. Circulating microRNAs can be regarded as hormones that convey epigenetic information and might affect gene expression in cells distant to the cellular microRNA source [15]. Membrane vesicles have been shown to enter other cells and induce changes in gene expression patterns [10]. Tumor cell-secreted microRNAs might be implicated in cell-to-cell communication within the tumor, affect the immune response, and facilitate angiogenesis, tumor invasion and metastatic propagation [16, 17].

The relevance of circulating microRNAs in healthy individuals is, however, entirely unknown. Here, we present a hypothesis on the potential relevance of circulating blood-borne microRNAs.

**Hypothesis: tumor surveillance by microRNAs**

The circulating microRNA profiles of healthy individuals have been analyzed in some studies and over 270 different microRNAs have been detected with highly variable expression in different studies on serum or plasma samples [9]. By comparing the relative abundance of these, some microRNAs can be established that are highly overrepresented by normalizing the data of different studies based on the rank orders of the raw expression data [9]. Among the microRNAs that are most abundant, using an arbitrary boundary, i.e., over tenfold overrepresented relative to the 20th most common microRNA in the ranking: *hsa-miR-451* (106-fold higher expression than that of the 20th microRNA in the ranking) [18], *hsa-miR-223* (11 to 338-fold) [19],
five studies analyzed in silico (Table 1), has been also in chronic lymphocytic leukemia [4]. miR suggesting its tumor suppressor activity [23–28]. The other (glioma, colorectal cancer, liposarcoma, osteosarcoma) cancer cell line, and the cellular context [29]. In gliomas and the Lewis lung and tumor suppressor activities depending on the tumor both hematologic and solid tumors, having both oncogenic presented to the others, major blood-borne microRNA that is relatively overrepresented). Hsa-miR-223 and hsa-miR-16 are also commonly found in three studies among the 20 most abundant microRNAs. Two further microRNAs worth mentioning: hsa-miR-486-5p that is abundant in three independent studies (up to 28.8-fold overrepresented), and hsa-miR-923 that is almost 200-fold overrepresented in one study (Table 1).

Among these microRNAs, several act predominantly as tumor suppressors. hsa-miR-16 is one of the most well-known tumor suppressor microRNAs originally described in chronic lymphocytic leukemia [4]. hsa-miR-16 is stably expressed in the blood, and it is one of the most widely used reference genes in studies on circulating microRNAs [22]. The hsa-let-7 family of microRNAs is regarded as a major group of predominantly tumor suppressor microRNAs that is relevant in lung cancer [5]. Beside hsa-let-7f that has been demonstrated to be relatively abundant compared to other circulating microRNAs [19], other members of this family like hsa-let-7a and hsa-let-7g have also been described as abundant in the circulation [18]. We have also found let-7 family members among the 20 most abundant microRNAs in our in silico analysis (hsa-let-7a, hsa-let-7b, hsa-let-7f, hsa-let-7g, hsa-let7i) (Table 1). hsa-miR-451, described to be highly abundant in the sera of Chinese individuals by Chen et al. [18] and also in four of five studies analyzed in silico (Table 1), has been also found to be down-regulated in different tumor tissues (glioma, colorectal cancer, liposarcoma, osteosarcoma) suggesting its tumor suppressor activity [23–28]. The other major blood-borne microRNA that is relatively overrepresented to the others, hsa-miR-223 has been implicated in both hematologic and solid tumors, having both oncogenic and tumor suppressor activities depending on the tumor and the cellular context [29]. In gliomas and the Lewis lung cancer cell line, hsa-miR-223 behaved as a potent tumor suppressor [30, 31]. The highest ranked microRNA in the study by Tanaka et al. [32], hsa-miR-638 shows tumor suppressor activity in gastric cancer [33]. The most abundant microRNA in Weber’s study, hsa-miR-335 displays antitumoral activity in a wide variety of different tumors including colorectal [34], gastric [35], ovarian [36] cancers and osteosarcoma [37]. The third most abundant hsa-miR-377 by Weber et al. [38] behaves as a tumor suppressor in metastatic prostate cancer cells. (There are no relevant data on the oncogenic relevance of the second most abundant hsa-miR-325 in Weber’s study.) Two further microRNAs found to be abundant in our in silico analysis also have tumor suppressor activity: hsa-miR-486-5p in breast [39] and lung cancer [40]; hsa-miR-923 in chronic lymphocytic leukemia [41].

It must be noted, however, that among the relatively most abundant microRNAs, microRNAs with predominant oncogenic properties can also be found like hsa-miR-21 [7] [with ninefold higher expression than the 20th microRNA in the study by Mitchell et al. [19] and also in three of five studies among the top 20 most abundant microRNAs in our in silico analysis (Table 1)]. Among the other relatively abundant microRNAs, several other microRNAs can be found with classical Janus-like activity (tumor suppressor or oncogene depending on the cellular context).

The predominant tumor suppressor activity of the most highly overexpressed microRNAs in the blood is intriguing. Is it possible that these microRNAs could inhibit malignant transformation? By entering transformed cells,
tumor suppressor microRNAs targeting genes involved in the regulation of cell cycle, cell proliferation, etc., might lead to decreased proliferation, cell cycle arrest or apoptosis induction (Fig. 1). It is hypothesized that potentially malignant cells frequently arise in healthy individuals, and these are destroyed mostly by the immune system according to the paradigm of cancer immune surveillance (cancer immunoediting) [42]. The antitumoral immunity is a very flexible and fast-acting response that eliminates cells potentially harmful to the host [43]. Could blood-borne microRNAs inhibit malignant transformation or proliferation by conveying epigenetic information? If yes, the circulating microRNA pool could present a continuous barrier to tumor formation.

As tissue microRNA dysregulation is considered to be an early event in tumorigenesis [15], alterations in the concentration of microRNAs (i.e., significant reduction in predominantly tumor suppressors) might also be implicated in tumor initiation. Tumor suppressive epigenetic information conveyed by blood-borne microRNAs could reprogram nascent tumor cells by repressing proliferation or inducing apoptosis early in their transformation process and might halt or prevent tumor formation. This hypothesized continuous inhibition of tumor formation might act together with the immune response. As genetic alterations happen much earlier than the immune response that depends on alterations in protein expression, the epigenetic way of tumor inhibition by circulating microRNAs could precede the immune cancer surveillance and complement it. This hypothetical action might add a further layer of host antitumor activity.

Anyway, an extensive research for identifying the mRNA targets of microRNAs isolated from healthy persons and cancerous patients might provide ideas on the tentative tumor suppressive or oncogenic mechanisms of circulating microRNAs, respectively.

Apart from this hypothetical reprogramming of nascent tumor cells in the very early phase of tumorigenesis, blood-borne microRNAs might also influence other, more advanced phases (hallmarks) of tumor formation including angiogenesis, invasion, etc. [44]. Circulating microRNAs might affect angiogenesis [45], and endothelial cells could be the most easily accessible targets cells for circulating microRNAs. It might even be supposed that the antitumoral immunity could be affected by blood-borne microRNAs, as well, and thereby blood-borne microRNAs might not only complement, but also might interact with immune cancer surveillance.

An interesting similar hypothesis on the relevance of circulating microRNAs in tumors has been put forward by Chen et al. [12], who observed that in the blood of cancer patients microRNAs with predominantly tumor suppressor activity are more abundant than oncogenic microRNAs. The relative abundance of tumor suppressor microRNAs can be viewed as a form of anti-cancer defense mechanism in advanced cancer patients [12]. Chen et al. proposed that the anti-cancer action of these microRNAs might be predominantly mediated via enhancing the antitumor immune response. Our hypothesis, on the other hand, concerns tumor suppressor microRNAs in healthy individuals, whereby these could constitute a form of antitumor surveillance reprogramming nascent tumor cells and inhibiting tumor formation in its early phase.

Counter arguments and problems

A major counter argument against this hypothesis could be the cellular context-dependent activity of microRNAs. Even microRNAs with predominant tumor suppressor activity could have oncogenic relevance in certain tissues. Our tenfold boundary (tenfold overrepresented to the 20th microRNA in ranking) for discussing the most relevant circulating microRNAs is certainly arbitrary, and among the microRNAs below this threshold, several others can be found having both oncogenic and tumor suppressor activity or even predominantly oncogenic like hsa-miR-21. The relative abundance of microRNAs with predominantly tumor suppressor activity in the over tenfold overrepresented group is, however, noteworthy.

Another major problem is related to the very low quantity of circulating microRNAs. Even the concentration of the most overrepresented circulating microRNAs is very low, and it is unknown whether microRNAs in such low concentration are potent enough to result in significant gene expression alterations in cells internalizing them. There are in vitro data supporting the gene expression modulating capacity of both membrane vesicle and lipo-protein-associated microRNAs [10, 46], but there are no findings whatsoever showing that microRNAs in the circulation can indeed mediate gene expression information to tissues.

A further issue is related to the affected cell populations. Apart from the endothelial and blood cells getting into direct contact with circulating microRNAs, what other cells could be affected and how? Most probably, microRNAs can traverse the capillary endothelium, as there are data that even exogenous microRNAs might pass the gastrointestinal epithelium and enter the circulation [47, 48]. The gastrointestinal transfer of microRNAs, however, is not universally accepted, and other research findings indicate that this process is not efficient [49]. Exosomes have been shown to traverse the blood–brain barrier [50]. It is not known, however, whether protein or HDL-bound microRNAs can also do the same. The molecular mechanisms responsible for these phenomena have not been defined,
yet. Nevertheless, the different forms of storage of microRNAs (unbound, extracellular vesicle bound or protein protected) might result in different half-lives of microRNAs. Moreover, the selectivity of the storage forms of different microRNAs cannot be excluded.

There are certainly interindividual and ethnic variations in microRNA profiles of healthy individuals as exemplified by the findings of different research groups (Table 1). Habits, e.g., smoking might significantly influence the microRNA profile, as well [51]. It is, therefore, difficult to establish a general “normal” profile. Methodological problems might also account for variations, since difficulties of standardized microRNA isolation, platform differences (microarray, real-time polymerase chain reaction-based techniques, next generation sequencing), and the choice for housekeeping might also affect the results.

It will be rather difficult to test this hypothesis experimentally. In vitro experiments could be conceived to test whether microRNAs could halt tumorigenesis or induce apoptosis in nascent tumor cells generated by, e.g., viral or chemical transformation induction processes in cell cultures. As our hypothesis relates to the inhibition of nascent tumor formation in vivo, animal tumor models should be examined. microRNAs with predominant tumor suppressor action could be administered to mouse tumor models (e.g., spontaneous or chemical induced tumors in immune-deficient mice) and the frequency of tumor formation could be tested. Several problems need to be addressed in these studies, e.g., form of administration, the concentration of the microRNA administered, potential off-target microRNA actions, etc. Alternatively, knockout or transgenic mouse models of selected microRNAs abundant in the circulation could be examined for spontaneous or induced tumor frequency. In the available knockout mouse models for hsa-miR-223 and hsa-miR-451, however, no increase in spontaneous tumor frequency has been reported [52, 53]. Longer observation periods and tumor induction might be envisaged in these models. The tumor surveillance by microRNAs, however, would not be a phenomenon involving only a single microRNA, rather microRNA sets, and therefore combinations of different microRNAs with tumor suppressor activity should be tested.

Conclusions

Here, we have presented a hypothesis on the potential relevance of circulating, blood-borne microRNAs in healthy individuals. Our hypothesis is based on the relative abundance of microRNAs with predominant tumor suppressor activity among the most highly overrepresented microRNAs in serum or plasma. Their potential activity as tumor suppressors might be intriguing. It must be noted, however, that we have highlighted only one potential activity of circulating microRNAs in healthy individuals. Circulating microRNAs might affect other major homeostatic mechanisms, i.e., immune response, hematopoiesis, etc. Further studies will be necessary to gain deeper insight into this fascinating field and to be able to explore the biological relevance of circulating microRNAs.

Acknowledgments

The authors are indebted to Dr. Peter M. Szabó MD PhD (Biometric Research Branch, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA) for performing the bioinformatics analysis of microRNA datasets. This study has been supported by a grant from the Hungarian Scientific Research Fund (OTKA, K100295). The authors would like to thank Prof. András Falus and Prof. Edit Buzás (Department of Genetics, Cell- and Immunobiology, Semmelweis University, Budapest) for their constructive comments.

Open Access

This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Alvarez-Garcia I, Miska EA (2005) MicroRNA functions in animal development and human disease. Development 132(21):4653–4662. doi:10.1242/dev.02073
2. Malumbres M (2013) miRNAs and cancer: an epigenetics view. Mol Aspects Med 34(4):863–874. doi:10.1016/j.mam.2012.06.005
3. Chen CZ (2005) MicroRNAs as oncogenes and tumor suppressors. N Engl J Med 353(17):1768–1771. doi:10.1056/NEJMip058190
4. Ageilant RI, Calin GA, Croce CM (2010) miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 17(2):215–220. doi:10.1038/cdd.2009.69
5. Boyerinas B, Park SM, Hau A, Murmann AE, Peter ME (2010) The role of let-7 in cell differentiation and cancer. Endocr Relat Cancer 17(1):F19–F36. doi:10.1677/erc-09-0184
6. Osada H, Takahashi T (2011) Let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 102(1):9–17. doi:10.1111/j.1349-7006.2010.01707.x
7. Hong L, Han Y, Zhang Y, Zhang H, Zhao Q, Wu K, Fan D (2013) MicroRNA-21: a therapeutic target for reversing drug resistance in cancer. Expert Opin Ther Targets 17(9):1073–1080. doi:10.1517/14728222.2013.819853
8. Gilad S, Meiri E, Yoge Y, Benjamin S, Lebano Y, Yerushalmi N, Benjamin H, Kushmir H, Cholak H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A (2008) Serum microRNAs are promising novel biomarkers. PLoS ONE 3(9):e3148. doi:10.1371/journal.pone.0003148
9. Reid G, Kirschner MB, van Sandwijnik N (2011) Circulating microRNAs: association with disease and potential use as biomarkers. Crit Rev Oncol/Hematol 80(2):193–208. doi:10.1016/j.critrevonc.2010.11.004
10. Redis RS, Calin S, Yang Y, You MJ, Calin GA (2012) Cell-to-cell miRNA transfer: from body homeostasis to therapy. Pharmacol Ther 136(2):169–174. doi:10.1016/j.pharmthera.2012.08.003
11. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF, Tewari M (2012) Blood cell origin of
Igaz, I. Igaz

circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer Prevent Res (Philadelpia, Pa) 5(3):492–497. doi:10.1158/1940-6207.capr-11-0370

12. Chen G, Wang J, Cui Q (2013) Could circulating miRNAs contribute to cancer therapy? Trends Mol Med 19(2):71–73. doi: 10.1016/j.trendsmolmed.2012.10.006

13. Allegra A, Alonci A, Campo S, Penna G, Petruccione A, Gerace D, Musolino C (2012) Circulating microRNAs: new biomarkers in diagnosis, prognosis and treatment of cancer (review). Int J Oncol 41(6):1897–1912. doi:10.3892/ijo.2012.1647

14. Jarry J, Schadendorf D, Greenwood C, Spatz A, van Kempen LC (2014) The validity of circulating microRNAs in oncology: five years of challenges and contradictions. Mol Oncol. doi:10.1016/j.molonc.2014.02.009

15. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA (2011) MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol 8(8):467–477. doi:10.1038/nrclinone.2011.76

16. Taylor DD, Gercel-Taylor C (2013) The origin, function, and diagnostic potential of RNA within extracellular vesicles present in human biological fluids. Front Genet 4:142. doi:10.3389/fgene.2013.00142

17. Ma R, Jiang T, Kang X (2012) Circulating microRNAs in cancer: origin, function and application. J Exp Clin Cancer Res 31:38. doi:10.1186/1756-9966-31-38

18. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of non-coding RNA transcripts in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006. doi:10.1038/cr.2008.282

19. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M (2008) Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105(30):10513–10518. doi:10.1073/pnas.0804549105

20. Hunter MP, Ismail N, Zhang X, Aguad BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jurjova D, Marsh CB (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3(1):e6904. doi:10.1371/journal.pone.0006904

21. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K (2010) The microRNA spectrum in 12 body fluids. Clin Chem 56(11):1733–1741. doi:10.1373/clinchem.2010.147405

22. Szabo DR, Luconi M, Szabo PM, Toth M, Szucs N, Horanyi J, Nagy Z, Mannelli M, Patocs A, Racz K, Igaz P (2014) Analysis of circulating miRNAs in adenocortical tumors. Lab Invest Pathol 94(3):331–339. doi:10.3835/labinvest.2013.148

23. Liu D, Liu C, Wang X, Ingvarsson S, Chen H (2014) MicroRNA-451 suppresses tumor cell growth by down-regulating IL6R gene expression. Cancer Epidemiol 38(1):85–92. doi:10.1016/j.canep.2013.12.005

24. Godlewski J, Bronisz A, Nowicki MO, Chiocca EA, Lawler S (2010) microRNA-451: A conditional switch controlling glioma cell proliferation and migration. Cell cycle (Georgetown, Tex) 9(14):2742–2748. doi:10.4161/cc.9.14.12248

25. Bitarte N, Bandres E, Boni V, Zarate R, Rodriguez J, Gonzalez-Huarriz M, Lopez I, JavierSola J, Alonso MM, Fortes P, Garcia-Foncillas J (2011) MicroRNA-451 is involved in the self-renewal, tumorigenicity, and chemoresistance of colorectal cancer stem cells. Stem Cells (Dayton, Ohio) 29(11):1661–1671. doi:10.1002/stem.741

26. Namlos HM, Meza-Zepeda LA, Baroy T, Ostenes IH, Kresse SH, Kuijler ML, Serra M, Burger H, Cleton-Jansen AM, Myklebost O (2012) Modulation of the osteosarcoma expression phenotype by microRNAs. PLoS ONE 7(10):e48086. doi:10.1371/journal.pone.0048086

27. Gits CM, van Kuijff PF, Jonkers MB, Boersma AW, Smid M, van Ijcken WF, Coindre JM, Chibon F, Verhoeef C, Mathijssen RH, den Bakker MA, Verweij J, Sleijfer S, Wiemer EA (2013) MicroRNA expression profiles distinguish liposarcoma subtypes and implicate miR-145 and miR-451 as tumor suppressors. Int J Cancer. doi:10.1002/ijc.28604

28. Xu H, Mei Q, Shi L, Lu J, Zhao J, Fu Q (2013) Tumor-suppressing effects of miR451 in human osteosarcoma. Cell Biochem Biophys. doi:10.1007/s10561-013-9783-5

29. Haneklaus M, Gerlic M, O'Neill LA, Masters SL (2013) miR-223: infection, inflammation and cancer. J Intern Med 274(3):215–226. doi:10.1111/joim.12099

30. Nian W, Ao X, Wu Y, Huang Y, Shao J, Wang Y, Chen Z, Chen F, Wang D (2013) miR-223 functions as a potent tumor suppressor of the Lewis lung carcinoma cell line by targeting insulin-like growth factor-1 receptor and cyclin-dependent kinase 2. Oncol Lett 6(2):359–366. doi:10.3892/ol.2013.1375

31. Glaspow SM, Laug D, Brawley VS, Zhang Z, Corder A, Yin Z, Wong ST, Li XN, Foster AE, Ahmed N, Deneen B (2013) The miR-223/nuclear factor I-A axis regulates glial precursor proliferation and tumorigenesis in the CNS. J Neurosci 33(33):13560–13568. doi:10.1523/jneurosci.0321-13.2013

32. Tanaka M, Oikawa K, Takanashi M, Kudo M, Ohyashiki J, Ohyashiki K, Kuroda M (2009) Down-regulation of miR-92 in human plasma is a novel marker for acute leukemia patients. PLoS ONE 4(5):e5532. doi:10.1371/journal.pone.0005532

33. Zhao LY, Yao Y, Han J, Yang J, Wang XF, Tong DD, Song TS, Huang C, Shao Y (2014) miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci. doi:10.1007/s10620-014-3087-5

34. Sun Z, Zhang Z, Liu Z, Qiu B, Liu K, Dong G (2014) MicroRNA-335 inhibits invasion and metastasis of colorectal cancer by targeting ZEB2. Med Oncol (Northwood, London, England) 31(6):982. doi:10.1007/s12032-014-0982-8

35. Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, Li D, Zhou Y (2014) The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol 45(1):197–208. doi:10.3892/ijon.2014.2415

36. Cao J, Cai J, Huang D, Han Q, Yang Q, Li T, Ding H, Wang Z (2013) miR-335 represents an invasion suppressor gene in ovarian cancer by targeting Bcl-w. Oncol Rep 30(2):701–706. doi:10.3892/or.2013.2482

37. Wang Y, Zhao W, Fu Q (2013) miR-335 suppresses migration and invasion by targeting ROCK1 in osteosarcoma cells. Mol Cell Biochem 384(1–2):105–111. doi:10.1007/s11010-013-1786-4

38. Formosa A, Markert EK, Lena AM, Italiano D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabagdiu AV, Melino G, Candi E, Hansel D, Beverina C, Ponzoni M, Gatter K, Borresen-Dale AL, Peralia M, Bukholm IR, Kristensen VN (2014) Deregulation of cancer-related miRNAs is a common event in both benign and malignant human breast tumors. Carcinogenesis 35(1):76–85. doi:10.1093/carcin/bgt333
Tumor surveillance by circulating microRNAs

40. Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, Stass SA, Xing L, Jiang F (2014) Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene 33(9):1181–1189. doi:10.1038/onc.2013.42

41. Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Liu P, Xu W, Li JY (2012) miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis 33(7):1294–1301. doi:10.1093/carcin/bgs179

42. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD (2002) Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 3(11):991–998. doi:10.1038/nm1002-991

43. Hamai A, Benlalam H, Meslin F, Hasmim M, Carre T, Akalay I, Janji B, Berchem G, Noman MZ, Chouaib S (2010) Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75(1):1–8. doi:10.1111/j.1399-0039.2009.01401.x

44. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. doi:10.1016/j.cell.2011.02.013

45. Finn NA, Searles CD (2012) Intracellular and Extracellular miRNAs in Regulation of Angiogenesis Signaling. Curr Angiogenesis 4(102):299–307. doi:10.2174/2211552811201040299

46. Rayner KJ, Hennessy EJ (2013) Extracellular communication via microRNA: lipid particles have a new message. J Lipid Res 54(5):1174–1181. doi:10.1194/jlr.R034991

47. Zhang L, Hou D, Chen X, Li D, Zhu L, Zhang Y, Li J, Bian Z, Liang X, Cui X, Yin Y, Wang C, Zhang T, Zhu D, Zhang D, Xu J, Chen Q, Ba Y, Liu J, Wang Q, Chen J, Wang J, Wang M, Zhang Q, Zhang J, Zen K, Zhang CY (2012) Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA. Cell Res 22(1):107–126. doi:10.1038/cr.2011.158

48. Etheridge A, Gomes CP, Pereira RW, Galas D, Wang K (2013) The complexity, function and applications of RNA in circulation. Front Genet 4:115. doi:10.3389/fgen.2013.00115

49. Snow JW, Hale AE, Isaacs SK, Baggish AL, Chan SY (2013) Ineffective delivery of diet-derived microRNAs to recipient animal organisms. RNA Biol 10(7):1107–1116. doi:10.4161/rna.24909

50. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJ (2011) Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol 29(4):341–345. doi:10.1038/nbt.1807

51. Takahashi K, Yokota S, Tatsumi N, Fukami T, Yokoi T, Nakajima M (2013) Cigarette smoking substantially alters plasma microRNA profiles in healthy subjects. Toxicol Appl Pharmacol 272(1):154–160. doi:10.1016/j.taap.2013.05.018

52. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O, Brummelkamp TR, Fleming MD, Camargo FD (2008) Regulation of progenitor cell proliferation and granulocyte function by microRNA-223. Nature 451(7182):1125–1129. doi:10.1038/nature06607

53. Patrick DM, Zhang CC, Tao Y, Yao H, Qi X, Schwartz RJ, Jun-Shen Huang L, Olson EN (2010) Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3zetas. Genes Dev 24(15):1614–1619. doi:10.1101/gad.1942810